Biotek-snakken — Oktober 2021
-
Så fejler Canakinumab, kan man let argumentere for, at sansynligheden for CAN04 bliver en succes er forringet. Men samtidig er Canakinumab og CAN04 forskelige på et afgørende punkt, som gør at CAN04 sagtens kan vise sig at virke mens Canakinumab ikke virker. Bliver sidste scenarie slutresultatet, så står Cantargia med et stærkt produkt, som kan vise sig, at virke i flere cancerformer ovenikøbet med en stor kunkurrent mindre (:-
-
Better Bet on COVID Pills: Merck or
Pfizer?https://www.proinvestor.com/investornyt/715853/better-bet-on-covid-pills-merck-or-pfizer -
Better Vaccine Stock: Moderna or Novavax?https://www.proinvestor.com/investornyt/715854/better-vaccine-stock-moderna-or-novavax
-
Pharmiva har lanseret Vernivia i Sverige.
https://www.proinvestor.com/index.php?p=debat_1&postid=97727 -
Disclaimer: Jeg købte mig ind i selskabet i 2018. Selskabet blev børsnoteret i marts 2021.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind